We conducted a randomized multicenter study to compare the efficacy and safety of two antibiotic regimens (cefepime [2 g bid.] plus amikacin or ceftazidime [2 g t.i.d.] plus amikacin) as first-line therapy for fever in patients with hematologic malignancies and neutropenia. A total of 353 patients were randomized according to a 2:1 (cefepime:ceftazidime) ratio. Two hundred-twelve patients in the cefepime group and 107 in the ceftazidime group (90% of all patients) were evaluable for efficacy. The polymorphonuclear neutrophil count was <100/mm3 on enrollment for 70% of the patients. The mean duration of neutropenia was 26 days. The efficacy in both study arms was comparable, although a trend in favor of cefepime was seen in terms of therapeutic success (response rate, 27% vs. 21% for the ceftazidime group). The overall response rate after glycopeptides were added to the regimens was 60% for the cefepime group and 51% for the ceftazidime group; the bacterial eradication rates were 81% vs. 76%, respectively, and the rates of new bacterial infections were 14% vs. 18%, respectively. We conclude that the combination cefepime/ amikacin is at least as effective as the reference regimen of ceftazidime/amikacin in this setting.
For at least 25 years, the use of a combination of antibiotics has been the cornerstone of therapy for febrile patients with cancer and severe treatment-induced neutropenia [1, 2] . The combination of a /3-lactam antibiotic with an aminoglycoside provided broad-spectrum coverage, particularly for gram-negative organisms [3] [4] [5] . With the introduction of extended-spectrum cephalosporins, it was hoped that monotherapy would provide adequate coverage with less toxicity at a lower cost.
Ceftazidime has been the agent most widely used alone for treatment of febrile neutropenic patients [6] [7] [8] [9] [10] . In Europe, ceftazidime combined with amikacin is often used as the firstline regimen for fever in high-risk patients (i.e., persistently and severely neutropenic [polymorphonuclear neutrophil count, <100/mm3]) [4] . Because of the increasing incidence of infections due to gram-positive organisms (especially coagulasenegative staphylococcus and streptococcus) in these patients [3] [4] [5] 11] , glycopeptide antibiotics have frequently been added to the therapeutic regimen [12] [13] [14] ; these antibiotics are given because ceftazidime has poor efficacy against methicillin-resistant staphylococci and many streptococci.
Cefepime is a new cephalosporin antibiotic with several potential advantages. Cefepime has low affinity for major chromosomally mediated ,8-lactamases and exhibits better resistance to hydrolysis by some 0-lactamases than do the third-generation cephalosporins [15] . In addition, cefepime's in vitro activity against gram-positive cocci (including Streptococcus pneumoniae isolates that are moderately resistant to penicillin G) has been shown to be better than that of ceftazidime and comparable to that of cefotaxime and ceftriaxone [16] .
Cefepime has activity similar to that of ceftazidime against Pseudomonas aeruginosa and equal to or better than that of ceftazidime against Enterobacteriaceae, and cefepime has the advantage of being active against gram-positive cocci, as do the older cephalosporins such as cefotaxime [16] [17] [18] . Considering the spectrum of pathogens encountered in neutropenic patients, cefepime should be a useful agent for these patients [19] .
We report the results of a randomized multicenter study in which intravenous cefepime was compared with intravenous ceftazidime; both drugs were used in combination with intravenous amikacin to treat febrile patients with hematologic malignancies and profound neutropenia.
Methods
This study was open, unblinded, and randomized. It was conducted according to the American and European Guidelines Downloaded from https://academic.oup.com/cid/article-abstract/24/1/41/348951 by guest on 26 December 2018 for the design of clinical trials on empirical antibiotic therapy for neutropenic patients [20] [21] [22] .
Patient eligibility. Any patient hospitalized in one of the 31 participating centers who had given written consent was eligible for the study if the following criteria were met: age, 18 years; presence of malignant hematologic disease; presence of chemotherapy-induced neutropenia, with a polymorphonuclear neutrophil (PMN) count that was 500/mm3 on enrollment or that was expected to be at this level within 48 hours; a temperature of _^-38°C at least two times in 8 hours or a temperature of a38.5°C once; an afebrile period of _^-72 hours before enrollment; and a life expectancy of months.
Patients were excluded if they were receiving systemic antibiotics during the 72 hours preceding the febrile episode, had known hypersensitivity to cephalosporins or aminoglycosides, were in blast crisis of chronic myeloid leukemia, were infected with HIV, or had renal failure (creatinine level, -1.8 mg/dL).
Patients with septic shock, CNS infection, or infection with organisms resistant to cefepime or ceftazidime were also excluded before randomization. Patients receiving nonabsorbable drugs for prophylactic gut decontamination were permitted in the study. Prophylaxis with antifungals (except for iv amphotericin B, which has possible pyretic effects) and antivirals was allowed according to the routine indications at the participating centers. Patients with solid tumors were excluded unless they were in the aplastic phase following autologous bone marrow transplantation. Each patient could be included in the study only once.
Randomization procedure. Patients were randomly assigned to receive either iv cefepime (2 g b.i.d.) or iv ceftazidime (2 g t.i.d.) together with iv amikacin (7.5 mg/kg b.i.d.) as a first-line regimen for fever. The randomization was done by center, with consecutive sealed envelopes and a 2:1 (cefepime:ceftazidime) randomization ratio to obtain a larger population for data on the safety of cefepime.
Clinical evaluation and classification of fever. Patients were evaluated clinically before randomization and then daily by the investigator at each center. The clinical data were collected on day 0, day 3, day 7, when the patient recovered from aplasia (PMN count, 1,000/mm 3 ), 4 days after discontinuation of the study treatment, and at any time if a clinical event led to a modification of the anti-infective therapy. Each episode was ultimately classified as fever of unknown origin, clinically documented infection, or microbiologically documented infection, according to the international guidelines [20] [21] [22] . New infections were defined as infections caused by a new pathogen from the original site of infection or by any pathogen from a new site of infection, either during study treatment or within 4 days of discontinuation of study therapy.
Bacteriologic procedures. At least two sets of blood cultures (blood was obtained from two different sites) were performed before patients began receiving the study treatment on day 0. Any blood culture isolate was considered a pathogen (this did not apply to coagulase-negative staphylococci, for which two positive cultures were required to establish pathogenicity). A bacteriologic sample was also obtained from any site of infection on day 0. These samples were collected again on day 3 from all patients. Further bacteriologic samples were obtained as necessary until eradication was documented or until treatment was changed. A bacteriologic sample was required at the time that the initial treatment was modified to assess the bacteriologic efficacy of the initial regimen.
All causative pathogens were tested for in vitro susceptibility to cefepime, ceftazidime, and amikacin by the Kirby-Bauer disk diffusion method or by determination of MICs. An isolate was considered resistant to cefepime or ceftazidime if the MIC was >32 mg/L or if the inhibitory zone was < 15 mm; it was considered susceptible to cefepime if the MIC was a 4 mg/L or if the inhibitory zone was _-21 mm. An isolate was considered resistant to amikacin if the MIC was > 16 mg/L or if the inhibitory zone was <15 mm, and it was considered susceptible to amikacin if the MIC was -8 mg/L or if the inhibitory zone was 17 mm [23] .
Study drug administration and antibiotic treatment schedule.
Each 2-g dose of cefepime or ceftazidime was diluted in 50-100 mL of sterile isotonic saline or 5% dextrose and infused over a 30-minute period. Amikacin was also administered over a 30-minute period immediately after the infusion of the cephalosporin when the infusions were concomitant. The duration of treatment was days when the treatment was efficacious. In the case of a satisfactory clinical response, treatment with amikacin could be stopped after 7 days. Treatment was then continued as monotherapy with the 0-lactam. The dosages of amikacin were adjusted at least weekly, according to standard recommendations.
Vancomycin (or teicoplanin in cases of known hypersensitivity to vancomycin) could be added to the initial study combination in several previously defined situations: (1) before day 3 if fever persisted and/or obvious signs of clinical deterioration (including the occurrence of septic shock, progression of infection, or the development of new foci) were observed; (2) after day 3, if fever persisted without isolation of a pathogen or if any of the above conditions were present; and (3) if a methicillinresistant coagulase-negative staphylococcus was isolated in at least two blood samples or if another cephalosporin-resistant gram-positive pathogen was isolated.
If a patient developed uncontrollable fever or infection at any time during the study, the clinician could add a glycopeptide to the study combination or entirely change therapy, but the reason had to be reported. When any antibiotic was added, the initial regimen was considered to have failed.
Evaluability criteria. The data initially collected by the investigator (or by the clinical research assistant of the unit) were reviewed and checked against source documents on site by a data manager. Every case report was then reviewed by two data managers and the coordinator of the study to determine patient eligibility, classify the initial febrile episode, and evaluate the response to therapy. All patients who received at least one dose of the study regimen were considered evaluable in terms of treatment safety. To be evaluable for treatment efficacy, the patients must have met the inclusion criteria, had the required bacteriologic samples obtained on day 0, and received the study drugs according to the mandated schedule. Patients with documented viral or fungal infection on day 0 were ineligible for evaluation.
Evaluation of response. Early efficacy was assessed for all patients at day 3, and overall response was assessed 4 days after treatment ended. Clinical response had occurred if the patient was afebrile during treatment and remained so until at least 4 days after treatment was discontinued, the clinical focus of infection present on day 0 had cleared, any initial pathogens were eradicated, and no other antibiotic was added to the regimen. Treatment failures were classified in two categories: those defined as the addition of a glycopeptide to the study regimen; and those defined as any modification to the regimen other than the addition of a glycopeptide.
Toxicity. The patients were carefully monitored for side effects, and all intercurrent events were reported. Determinations of hematologic and biochemical parameters and a urinalysis were requested at least on days 0, 3, and 7, and 4 days after termination of study therapy. Renal function was judged on the basis of serum creatinine levels, and hepatic function was assessed on the basis of the levels of serum bilirubin, transaminases, and alkaline phosphatase. Renal and hepatic functions were graded according to the World Health Organization (WHO) criteria [24] .
Statistical analysis. Efficacy analyses were performed for all patients who met the criteria for evaluation of efficacy. Evaluable patients with a microbiologically documented infection were analyzed with respect to the eradication rate for the isolated pathogens. Safety analyses were performed for all patients who received at least one dose of the study regimen.
Pretreatment characteristics were assessed in the evaluation of efficacy. Categorical variables among these characteristics were compared between treatment groups with use of Fisher's exact test. Continuous variables were compared between treatment groups with use of Wilcoxon's rank sum test.
The determination of efficacy was primarily based on the success rate of the study regimen; the success rates between treatment arms, adjusted for the classification of the initial infection, was done with use of the Mantel-Haenszel test. In addition, 95% confidence intervals for the difference in success rates between treatment groups were computed. The bacteriologic eradication rate was calculated for all pathogens isolated at baseline.
Secondary efficacy parameters included the reason for adding a glycopeptide, adding another drug(s) to the regimen, the proportion of patients with a new infection, and the susceptibility of the pathogens to the study antibiotics. Parameters used for the evaluation of safety included the occurrence of intercurrent clinical events, the incidence of withdrawals from the study because of intercurrent clinical events, the death rate, and worsening of laboratory test results (defined as a worsening of at least one level based on the WHO grade of baseline test results vs. worst on-study test results). Categorical variables among these parameters were compared between the two treatment groups with use of Fisher's exact test and Wilcoxon's rank sum test for continuous variables. Comparisons between the two treatment groups were conducted by using a statistical level of 5% (two-tailed).
Results
Between 1 October 1992 and 31 October 1993, 353 patients from 31 French centers were enrolled in this study. The number of patients enrolled per center ranged from 1 to 36 (median number enrolled, 10). A total of 242 patients were randomized to the cefepime/amikacin group, and 111 to the ceftazidime/ amikacin group.
Thirty four patients (9.6%) were inevaluable in terms of efficacy for the following reasons: 15 were ineligible (the duration of neutropenia was <5 days [5 patients ], viral or fungal infection was documented [4] , fever was absent or the PMN count was >500/mm 3 on enrollment [1 each] , or no blood cultures were done or septic shock was present on day 0 [2 each]), 12 had protocol violations (the incorrect dosage was given [5 patients] , unjustified additional antibiotics were administered [5] , or treatment was discontinued too early [2] ), and 7 were inevaluable for response (intercurrent events occurred [5 patients] or records were lost [2] ).
Two of the 34 inevaluable patients had septic shock on enrollment (one case was due to methicillin-susceptible Staphylococcus aureus and the other to multidrug resistant Streptococcus mitis). Because of the low rate (9.6%) of inevaluable patients, we chose to analyze the results on a per protocol basis.
The enrollment characteristics of the 319 remaining evaluable patients are summarized in table 1. There were 212 patients in the cefepime/amikacin arm and 107 in the ceftazidime/amikacin arm.
A total of 206 patients (65%), equally distributed in the cefepime arm (67%) and in the ceftazidime arm (61%), were receiving prophylaxis for gut decontamination before inclusion. This prophylaxis consisted of monotherapy with an aminoglycoside, a glycopeptide, or a polypeptide for 77 patients (37%) or therapy with two, three, or four agents including various combinations of aminoglycosides, glycopeptides, and polypeptides for 129 (63%) of the patients.
The groups were comparable in terms of age, sex, underlying malignancies, treatment, and median and mean number of PMNs on enrollment. Patients with hematologic malignancies constituted 95% of each group; -60% were neutropenic secondary to chemotherapy and 40% were neutropenic secondary to receiving bone marrow transplants, the majority of which were autologous. Forty percent of the recipients of marrow transplants had received total body irradiation. * These numbers were calculated on the basis of only 190 patients in the cefepime group and 95 in the ceftazidime group. The other 34 patients included 13 who died of aplasia (median time to death, 23 days after treatment), 19 who were still neutropenic at the last follow-up (median time, 13 days after treatment), and 2 with PMN counts of 500/mm 3 on the last day of treatment who were discharged without further follow-up.
Almost every patient had a central venous catheter in place. The majority of patients received prophylactic gut decontamination and antifungal antibiotics. Only 28% received hematopoietic growth factors. Seventy percent had PMN counts of < 100/mm3 at inclusion. The median nadir of the PMN counts during treatment was 10-20/mm 3 . The overall median duration of neutropenia was 21 days (23 days in the cefepime group and 19 in the ceftazidime group; P = .07). The febrile episodes were ultimately classified as fever of unknown origin in 60% of the cases, clinically documented infection in 9%, and microbiologically documented infection in 31%.
The mean (±SD) duration of treatment with the /3-lactam was 13 ± 7-8 days in both groups, and the mean (± SD) duration of treatment with amikacin was 11 ± 6 days in both groups. The frequency with which antivirals alone (16% in both groups), antifungals alone (21%-23%), or both (13%-16%) were added during treatment was similar in the cefepime and ceftazidime groups.
The survival rate 1 month after the last study-treatment dose (assessed with respect to the whole population of the 353 patients) was 95% in the cefepime arm and 96% in the ceftazidime arm. Only one patient died during treatment; this patient was in the cefepime group and had refractory acute myeloid leukemia and pulmonary aspergillosis documented post-mortem.
During the 30 days after treatment, 12 patients (5%) in the cefepime group and 4 (4%) in the ceftazidime group died. For three of these patients (two in the cefepime group and one in the ceftazidime group), the initial infection contributed to the fatal outcome. The study treatment had been changed for all three within 2 days of enrollment because they developed septic shock. The remaining 13 patients died of their underlying malignancies.
Clinical response. A first evaluation was done on day 3. Table 2 summarizes the antibiotic regimens administered to the patients on day 3. Two-thirds of the patients (149 [70%] in the cefepime arm and 72 [67%] in the ceftazidime group) were still receiving the study combination without any additional antibiotics on day 3. Of these patients, 22 in the cefepime arm and 12 in the ceftazidime arm were receiving antifungals and/or antivirals on day 3.
We performed the final evaluation 4 days after the study treatment ended (table 3) . A clinical response to the two-drug combination occurred in 80 of the 319 patients (27% of patients in the cefepime arm and 21% in the ceftazidime arm). These 80 patients did not receive any other antibiotic until completion of the study treatment. The difference observed between the two arms was not statistically significant. Response was also comparable for the two arms whether the episodes were classified as fever of unknown origin, clinically documented infection, or microbiologically documented infection.
Two hundred thirty-nine patients failed to respond to the initial regimen. Thirty of these patients (19 [9%] in the cefepime arm and 11 [10%] in the ceftazidime arm) received a completely different regimen than the study combination, either according to the clinician's judgment (23 cases) or because a pathogen was resistant to the study drugs (7 cases). Fourteen of these 30 patients (11 in the cefepime arm and 3 in the ceftazidime arm) received one or two doses of glycopeptides before the study treatment was switched. The study regimen was considered a failure for the 30 patients who were switched to another regimen.
A glycopeptide was added to the study combination for the remaining 209 patients (64% in the cefepime arm and 68% in (7) NOTE. CDI = clinically documented infection; FUO = fever of unknown origin; MDI = microbiologically documented infection.
* None of the differences observed between the two study arms was statistically significant.
t No. of patients with characteristic/no. of patients who received indicated regimen (%). the ceftazidime arm). Vancomycin was administered to 93% of these patients, and teicoplanin was administered to 7%, equally distributed by treatment group. In most cases (74% of patients in the cefepime arm and 81% in the ceftazidime arm) the glycopeptide was added before day 7. The reasons for the addition of a glycopeptide are summarized in table 3 and were similar in both arms. One-half of the patients failed to respond to the glycopeptide and either remained febrile until recovery from neutropenia or were changed to other regimens. The other half of the patients (70 of 136 in the cefepime group and 32 of 73 in the ceftazidime group) responded to the glycopeptide without any other modification of antibiotics.
Finally, 187 patients (59%) completed treatment with or without the addition of glycopeptides; the frequency of this event was the same in both arms (i.e., 126 of 212 patients in the cefepime group and 61 of 107 patients in the ceftazidime group). Treatment was discontinued before completion of the study for 132'patients (41%: 86 in the cefepime group and 46 in the ceftazidime group). The reasons for withdrawal from the study were a poor clinical response that was unlikely to be affected by the addition of glycopeptides or antifungals (65 patients in the cefepime group and 37 in the ceftazidime group); recovery of a resistant pathogen (12 in the cefepime group and 2 in the ceftazidime group); the occurrence of adverse events (7 in the cefepime group and 7 in the ceftazidime group); resolution of aplasia (3 in the cefepime group); and a protocol violation (1 in the cefepime group).
The frequency with which antivirals alone, antifungals alone, or both were added during treatment with the study regimen was comparable for both groups: 16% of patients in both groups received antivirals alone; 21% in the cefepime group and 23% in the ceftazidime group received antifungals alone; and 16% in the cefepime group and 13% in the ceftazidime group received both types of agents. In considering both the patients who responded to the study regimen alone and those who responded to the study regimen plus a glycopeptide, the overall response rate increased from 27% to 60% (127 of 212 patients) in the cefepime arm and from 21% to 51% (55 of 107) in the ceftazidime arm (P = .15).
Microbiological response. Microbiological documentation of infection was possible for 33% of the patients in the cefepime arm and 28% in the ceftazidime arm. Eighty-nine percent of the infections were diagnosed on the basis of positive blood cultures. A total of 114 pathogenic strains were. isolated from the time of study entry. They are listed in table 4, along with their susceptibilities to the study drugs. Seventy-eight were gram-positive cocci; 43 of these isolates were staphylococci, 49% of which were methicillin resistant. Thirty-six were gramnegative organisms, 56% of which were Escherichia coli. There were only five infections due to P. aeruginosa; all occurred in the cefepime group. The proportion of gram-positive and gramnegative strains was similar in the two treatment groups.
Of the pathogens isolated, 72% were susceptible to cefepime and 67% were susceptible to ceftazidime by the disk diffusion method (table 4) . Sixty-two percent of gram-positive cocci and 94% of the gram-negative rods were susceptible to cefepime, and 51% of the gram-positive cocci and 100% of the gramnegative rods were susceptible to ceftazidime. Ninety-four percent of the gram-negative rods and 39% of the gram-positive cocci were susceptible to amikacin. The susceptibility to amikacin was similar in both groups.
Before the addition of a glycopeptide to the study regimen, 81% of the pathogens initially isolated were eradicated in the cefepime group (74% of the gram-positive organisms and 92% of the gram-negative organisms) (table 5). Nineteen percent of the organisms (including 8 of the 12 methicillin-resistant coagulase-negative staphylococci) persisted. It is noteworthy that all five patients with P. aeruginosa infection (four with septicemia and one with gastrointestinal tract infection) were randomized to the cefepime group. Two of these pathogens were eradicated, two persisted, and in one case response could not be determined. No patient died of P. aeruginosa infection.
In the ceftazidime group, 76% of the pathogens initially isolated (70% of the gram-positive organisms and 100% of the gram-negative organisms) were eradicated before the addition of a glycopeptide. Seven (24%) (including three of the six methicillin-resistant coagulase-negative staphylococci) persisted. [1] ) and in one case to the worsening of pneumonia after 12 hours of the study regimen. 1 Includes all initially enrolled patients (353) up to 1 month after treatment.
Among the 99 patients with microbiologically documented infections, 63 had infections due to gram-positive organisms, 31 had infections due to gram-negative organisms, and five had mixed infections. Among the 63 patients with gram-positive infections, the rates of clinical response to the study regimen were 19% in the cefepime group and 5% in the ceftazidime group. A glycopeptide was added to the regimen in 63% of the cefepime cases and in 70% of the ceftazidime cases. Thereafter, the rates of clinical response were 58% and 35% in the cefepime and ceftazidime groups, respectively.
Among the 31 patients with gram-negative infections, the rates of response to the study regimen were 30% and 50%, respectively; after the addition of a glycopeptide, the total response rates were 61% and 88%, respectively. None of these differences were statistically significant. The five patients with mixed infections included two cases in the cefepime group and one case in the ceftazidime group who responded to treatment and one each in the cefepime and ceftazidime arms for whom treatment failed.
New bacterial infections. Overall, 15% of patients (30 [14%] in the cefepime arm and 19 [18%] in the ceftazidime arm) experienced new microbiologically documented infections during treatment (table 6) . Sixty-nine pathogenic strains were isolated from these patients. Of these strains, 38 were recovered from blood cultures. Seventy-three percent were resistant to cefepime and 75% to ceftazidime. No death was related to any of these infections.
Antibiotic-related toxicity. The intercurrent events that may or may not have been related to the combinations, with or without the addition of glycopeptides, are summarized in table 7. There was no difference between the study regimens. Treatment was stopped because of intercurrent events in 25 Table 4 . Pathogenic strains isolated at study enrollment from febrile, neutropenic patients receiving cefepime/amikacin or ceftazidime/ amikacin: in vitro susceptibility to cefepime, ceftazidime, and amikacin, as determined by the disk diffusion method. (42) * Four strains were not tested against all three study drugs. t Numbers are zone of inhibition in mm. S All methicillin-resistant staphylococci were considered resistant to the three drugs regardless of the in vitro susceptibility results.
cases. The main reason was rash (18 patients, two-thirds of whom were receiving vancomycin). In the cefepime arm there were 12 cases of rash, two of pneumonia, one of veno-occlusive disease, one of hepatic and renal failure, one of cerebral hemorrhage, and one of septic shock. In the ceftazidime group, there were six cases of rash and one of cardiac failure. A worsening of biochemical parameters was observed in <7% of cases, with comparable frequency in both groups.
Discussion
In this study we compared the combination of cefepime (2 g b.i.d.) plus amikacin with that of ceftazidime (2 g t.i.d.) plus amikacin in a group of 319 patients, 95% of whom had hematologic malignancies and severe, protracted treatment-induced neutropenia and fever. The pathogens isolated from the patients with microbiologically documented infections were predominantly gram positive, as has been observed in many recent trials. Only 36 (32%) of 114 organisms were gram negative; in vitro susceptibility testing showed that all but three were susceptible to both study agents and amikacin. Sixty-eight percent of the pathogens were gram positive; 36% of them were resistant to cefepime, 45% were resistant to ceftazidime, and 59% were resistant to amikacin.
Of the new bacterial infections that occurred during treatment, 74% in the cefepime group vs. 80% in the ceftazidime group were due to gram-positive organisms as well. A glycopeptide was added to the initial combination for 64% of the patients in the cefepime group and 68% of those in the ceftazi- dime group, increasing the response from 27% to 60% in the cefepime arm and from 21% to 51% in the ceftazidime arm.
The results of this study were comparable between the two arms in terms of clinical response, rates of bacteriologic eradication, incidence of new infection, and survival. Moreover, the results of the safety evaluation show that cefepime in combination with amikacin is well tolerated in febrile, neutropenic patients with hematologic malignancies.
In fact, a trend toward better results with the cefepime combination (better clinical response, lower frequency of addition of a glycopeptide, and a lower rate of new bacterial infections) was observed for all major endpoints despite the fact that the duration and severity of neutropenia were greater in this group. However, a statistically significant difference between the two groups could not be demonstrated for these endpoints, probably because of the sample size and decreased statistical power due to the randomization ratio (twice the number of patients were included in the cefepime group as in the ceftazidime group).
If the 9% difference observed between the two arms in terms of the overall response rates after addition of glycopeptides is considered alone (this difference was even greater than the 6% difference observed between the two groups in terms of response to the strict study regimen), 1,123 evaluable patients would need to be studied to show, with 80% of probability, that this difference is statistically significant. It would be unrealistic to attempt to enroll such a large number of patients in France during a 1-year period.
Previous studies with ceftazidime and cefepime have often produced better results than were obtained in the present series [6-9, 19, 25] . During the 1980s, several studies were conducted to compare ceftazidime with combination therapy [6] [7] [8] [9] . At that time, a higher proportion of gram-negative organisms were being recovered, and the degree of neutropenia in the patients studied was less severe than in the present study [3, 6, 7] . The overall response rate was reported to be 49%-83%. Since then, there has been a remarkable increase in the proportion of gram-positive organisms recovered from neutropenic patients, particularly methicillin-resistant staphylococci and streptococci that are only moderately susceptible or are resistant to penicillin [11, [26] [27] [28] [29] . Cefepime has been studied as monotherapy in the hope of obtaining improved results in the treatment of gram-positive infections while maintaining good antipseudomonal coverage [19, 25] . The response rates in these studies varied from 43%-71%. The 71% response rate reported by Eggimann et al. [25] could reflect differences in the populations studied as well as in the dosages. In their study, 37% of patients did not have hematologic maligndncies and neutropenia was less severe (PMN count, <1,000/mm3) and of shorter duration (median duration, 8 days) than in the present study. In addition, the dosage of cefepime used as monotherapy was 2 g . three times daily, which was 50% higher than the dosage (in combination with amikacin) used in the present study. Finally, the success rates observed in our series seem to be low when compared with previous series.
On the other hand, our patients were clearly at higher risk than were those in previous series, as reflected by underlying conditions, therapies, and duration and severity of neutropenia. For example, it is unusual for bone marrow transplant recipients, who represented 41% of our patients, to go through a 3-week period of profound neutropenia, fever, and severe mucositis while receiving the same regimen until they recover from aplasia. Thus, differences in the recruitment of patients and in the way the responses are evaluated and the results are presented make comparisons difficult.
Our study is, to our knowledge, the first comparison of cefepime with ceftazidime, used in combination with aminoglycosides, in high-risk neutropenic patients, and it is to date the largest trial of neutropenic patients treated with cefepime. Cefepime offers the advantage of having a high level of in vitro activity against gram-negative pathogens (similar to that of ceftazidime or other third-generation cephalosporins) while having better activity against gram-positiye pathogens [15] [16] [17] [18] [19] . We were expecting to find a statistically significant advantage of cefepime but were unable to demonstrate one even though the incidence of infections due to gram-positive organisms was high (64% of the microbiologically documented infections and 20% of all evaluable episodes).
It is noteworthy that two-thirds of our patients received glycopeptides (64% in the cefepime arm and 68% in the ceftazidime arm), more often for unexplained persistent fever than for microbiological reasons. We believe that this high-level use of glycopeptides, which is widespread in France either as firstline treatment or as adjunctive therapy that is added by days 3 or 4 if fever persists, could have obscured any benefit of cefepime therapy for gram-positive infections.
The increasing frequency of infections due to gram-positive organisms especially streptococcal infections in neutropenic patients has been noted by several teams of investigators, and the situation was recently reviewed by Bochud et al. [11] . Viridans streptococcus septicemia may represent n28% of bacteremias in neutropenic patients. Factors found to be associated with these infections include profound neutropenia, mucositis, therapy with high-dose arabinosylcytosine, quinolone prophylaxis, and use of antacids or H2 antagonists; all of the latter agents are frequently part of treatment regimens for hematologic malignancy [6, 29] .
Ceftazidime and similar compounds are theoretically not adequate for patients with these risk factors; ureidopenicillins would provide more reliable coverage but may place patients at higher risk of developing gram-negative infections. Glycopeptides are always effective in vitro against viridans streptococci, but their bactericidal activity is usually slower than that of penicillins. Further studies with newer cephalosporins such as cefepime may result in improved treatment of these infections.
The present study shows that cefepime, at a lower dose and frequency of administration (2 g b.i.d.) is at least as effective Table 7 . Clinical intercurrent events and biochemical abnormalities possibly related or of unknown relationship to therapy for all febrile, neutropenic patients receiving cefepime/amikacin or ceftazidime/ amikacin.
